Dallas, TX (PRWEB) July 28, 2008
The US Food and Drug Administration (FDA) has granted 510(k) clearance for the Exotherme 980 & Endotherme 980 laser equipment.
The MedSurge Advances (MSA) technology known as Exotherme and Endotherme is a 980 nm continuous wave diode laser that can be adjusted from 6 watts to 25 watts of power. The Endotherme laser treats greater saphenous/superior saphenous leg veins and the Exotherme laser treats teleganectasia (spider leg veins). Both Endotherme and Exotherme run off the same laser platform as Lipotherme™ which received FDA Clearance in April 2008.
"We are delighted to have received FDA Clearance for Exotherme and Endotherme. The 980 laser platform is a highly adaptable technology that allows physicians to easily switch from performing laser lipolysis to treating greater saphenous veins and spider leg veins simply by changing hand pieces and Smartcards, the "brains" behind the technology", says Scott Day, Chairman, CEO and President of MedSurge Advances.
MedSurge Advances, the nation's largest independent provider of aesthetic medicine products and services to physicians, has exclusive rights to market the device in the US. Osyris, a cutting-edge French manufacturer of lasers for healthcare and industrial applications, developed Lipotherme for the European market and is now delighted to have partnered with MSA to introduce it to the US.
For media inquiries, please contact Rob Huckels at 214.540.3807 or rhuckels @ medsurgeadvances.com.
About MedSurge Advances:
Based in Dallas, MedSurge Advances helps physicians across the United States build and manage their practices in aesthetic medicine, one of the fastest-growing healthcare segments. Since its founding in 2002, MedSurge Advances has provided technology and business resources for more than 330 physicians in 42 states who have started stand-alone businesses or added aesthetic procedures to their existing practices. For more information, contact MedSurge Advances at 972.720.0425, or visit http://www.medsurgeadvances.com.
# # #